Trabectedin: novel insights in the treatment of advanced sarcoma.

about

Trabectedin: novel insights in the treatment of advanced sarcoma.

Item

http://www.wikidata.org/entity/Q38206396

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Trabectedin: novel insights in the treatment of advanced sarcoma.

@en

type

Item

label

Trabectedin: novel insights in the treatment of advanced sarcoma.

@en

prefLabel

Trabectedin: novel insights in the treatment of advanced sarcoma.

@en

P1476

Trabectedin: novel insights in the treatment of advanced sarcoma.

@en

P2093

Anthony Elias

http://www.w3.org/2001/XMLSchema#string

Csaba Gajdos

http://www.w3.org/2001/XMLSchema#string

P2860

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

ET-743: a novel agent with activity in soft tissue sarcomas.

Histology-driven chemotherapy of soft-tissue sarcoma.

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

P2888

s11912-014-0387-z

P304

387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-014-0387-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jay Patrick Lopez

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1006968126

http://www.w3.org/2001/XMLSchema#string

P698

24756367

http://www.w3.org/2001/XMLSchema#string

P921

trabectedin